Big data reveals Real-World CML treatment patterns in seniors

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. L Cohort: * Patients had at least one diagnosis for CML (International Classification of Diseases, 10th Revision, Clinical Modification \[ICD-10-CM\]: C92.1x) during the observation period. * Patients ≥18 years of age as of the first CML diagnosis. * Patients received imatinib, dasatinib, nilotinib, or bosutinib in 1L. * Patients initiated 1L within a maximum of 3 months following the first observed CML diagnosis. * Patients had at least 12 months of continuous enrollment prior to the index date. * Patients had at least 6 months of continuous enrollment post index date (including index date). 2. L Cohort: * Patients in the 1L cohort. * Patients received imatinib, dasatinib, nilotinib, bosutinib, ponatinib or asciminib in 2L. * Patients with at least 12 months of continuous enrollment prior to the index date. * Patients with at least 6 months of continuous enrollment post index date (including index date). Exclusion criteria: 1. L Cohort: * Patients with medical services with a procedure code for imatinib any time during the observation period. * Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time in the baseline period before the 1L initiation. * Patients with a medical claim associated with a clinical trial drug during the baseline period before the 1L initiation up to the end of the observation period. * Patients who received chemotherapy, or a TKI of interest or had a hematopoietic stem cell transplantation (HSCT) during the baseline period before 1L initiation. 2. L Cohort: * Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time before the 2L initiation.